<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Patients with advanced gastric cancer and positive peritoneal cytology and/or peritoneal dissemination are deemed to be incurable and to hold dismal prognosis. So far, the only treatment option for these patients has been palliative systemic (chemo)therapy. However, for the last three decades, great progress has been made in attempts to treat (potential) peritoneal dissemination by means of complete cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) after preoperative systemic therapy. This review is focused on the recent achievements of this multimodal strategy. Additionally, the review stands as background for the 4<sup>th</sup> International Conference “Advances in Surgical Oncology” that was held at the Medical University of Lublin (Poland) in November 2017, and dedicated to cytoreductive surgery and HIPEC for advanced gastric cancer.</p></abstract>

Patients with advanced gastric cancer and positive peritoneal cytology and/or peritoneal dissemination are deemed to be incurable and to hold dismal prognosis. So far, the only treatment option for these patients has been palliative systemic (chemo)therapy. However, for the last three decades, great progress has been made in attempts to treat (potential) peritoneal dissemination by means of complete cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) after preoperative systemic therapy. This review is focused on the recent achievements of this multimodal strategy. Additionally, the review stands as background for the 4th International Conference “Advances in Surgical Oncology” that was held at the Medical University of Lublin (Poland) in November 2017, and dedicated to cytoreductive surgery and HIPEC for advanced gastric cancer.

Treatment of peritoneal metastases from gastric carcinoma

Current Issues in Pharmacy and Medical Sciences

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

{"article-title":"Treatment of peritoneal metastases from gastric carcinoma"}

Patients with advanced gastric cancer and positive peritoneal cytology and/or peritoneal dissemination are deemed to be incurable and to hold dismal prognosis....

Treatment of peritoneal metastases from gastric carcinoma

Publié en ligne: 09 mars 2018

Pages: 173 - 179

Reçu: 22 déc. 2017

Accepté: 29 déc. 2017

DOI: https://doi.org/10.1515/cipms-2017-0032

Mots clés
gastric cancer, peritoneal metastases, gastrectomy, hyperthermic intraperitoneal chemotherapy, cytoreductive surgery

© 2017 Wojciech P. Polkowski et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Treatment of peritoneal metastases from gastric carcinoma

Publié en ligne: 09 mars 2018

Pages: 173 - 179

Reçu: 22 déc. 2017

Accepté: 29 déc. 2017

DOI: https://doi.org/10.1515/cipms-2017-0032

Mots clésgastric cancer, peritoneal metastases, gastrectomy, hyperthermic intraperitoneal chemotherapy, cytoreductive surgery

© 2017 Wojciech P. Polkowski et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Mots clés
gastric cancer, peritoneal metastases, gastrectomy, hyperthermic intraperitoneal chemotherapy, cytoreductive surgery